TRVITrevi Therapeutics, Inc.

$17.93

Who owns TRVI

198 institutions reported holding TRVI for 2026Q1, together 93% of the company, more than the 182 a quarter earlier.

198

Institutions reporting a position · as of 2026Q1 · up from 182 the quarter before

Shares held by institutions
134.9M

Shares held by institutions · 93% of the company · long US equity positions only, as reported on Form 13F

Reported value
$1.61B

Reported value · at 2026-03-31 prices, not today's

Top 5 holders
33%

Top 5 holders · of the whole company, between five filers

Details
Reporting quarter2026-03-31
2026Q1
Quarters on record
28
New positions
35
Positions exited
25
Added to
60
Reduced
57
Top 10 holdersof the company
48%
Institutional ownership by quarter, 2019Q2 to 2026Q1
QuarterFilersSharesReported value
2026Q1198134.9M$1.61B
2025Q4182130.3M$1.63B
2025Q3162129.3M$1.18B
2025Q2152114.6M$627M
2025Q113688.1M$554M
2024Q410979.5M$330M
2024Q39358.1M$194M
2024Q27755.9M$167M
2024Q18051.6M$178M
2023Q46352.2M$70M
2023Q35548.7M$106M
2023Q25348.8M$117M
2023Q13643.5M$80M
2022Q43743.2M$83M
2022Q34045.8M$70M
2022Q23228.8M$81M
Largest reported holders, 2026Q1
HolderShares% of companyValue
NEA Management Company, LLC13.2M9.1%$158M
BlackRock Inc.10.2M7.0%$122M
Frazier Life Sciences Management, L.P.9.9M6.8%$119M
FMR LLC8.0M5.5%$96M
VANGUARD GROUP INC6.8M4.7%$81M
WELLINGTON MANAGEMENT GROUP LLP5.2M3.6%$62M
Vivo Capital, LLC5.1M3.5%$61M
Marshall Wace LLP4.0M2.7%$47M
Rubric Capital Management LP3.7M2.5%$44M
MPM BIOIMPACT LLC3.3M2.3%$39M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…